ETFs positioned on Ipsen

Name YTD change Weight AuM
+13.49%-.--% 27,154 M€
+8.65%-.--% 92 M€
+13.56%-.--% 13 M€
+6.91%-.--% 49 M€
+1.69%-.--% 51 M€
+11.80%-.--% 66 M€
+12.41%-.--% 24,432 M€
+8.98%-.--% 75 M€
+11.17%-.--% 67 M€
+10.88%-.--% 6 M€
+10.68%-.--% 1,193 M€
+11.45%-.--% 6,576 M€
+12.17%-.--% 3,469 M€
+14.43%-.--% 5,871 M€
0.00%4.67% 8 M€
+51.85%3.96% 215 M€
+15.36%3.25% 23 M€
+14.78%1.94% 31 M€
+8.58%1.94% 31 M€
+8.85%1.75% 574 M€
+13.03%1.54% 18 M€
+14.35%1.52% 17 M€
+13.22%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+9.85%0.98% 125 M€
+11.23%0.87% 730 M€
+9.15%0.83% 55 M€
+8.15%0.83% 20 M€
+17.66%0.79% 1,260 M€
+12.73%0.78% 103 M€
+11.37%0.59% 140 M€
+5.83%0.58% 38 M€
+9.40%0.54% 51 M€
+11.41%0.53% 40 M€
+9.56%0.5% 23 M€
+14.97%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535